Skip to main content

1 Result(s)

within Nava Siegelmann-Danieli Remove this filter Pharmacy Remove this filter

and

  1. Article

    Open Access

    The reimbursement process in three national healthcare systems: variation in time to reimbursement of pembrolizumab for metastatic non-small cell lung cancer

    In this article, we focus on the reimbursement process, and as an example, characterize the time to reimbursement of pembrolizumab, a PD-1 immune checkpoint inhibitor for treatment of metastatic NSCLC from public...

    Sarah Sharman Moser, Frank Tanser… in Journal of Pharmaceutical Policy and Pract… (2023)

    Download PDF (910 KB) View Article